Another study showed that genetic variants mimicking LDL-C-lowering and triglyceride-lowering therapies play a role in decreasing atherosclerotic cardiovascular disease (ASCVD) risk for similar changes in apoB levels, despite the fact that plasma LDL-C and triglyceride levels showed different patterns of change [21]. Here, APOB is linked to atherosclerosis.